Compare SPG & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPG | BDX |
|---|---|---|
| Founded | 1960 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1B | 55.1B |
| IPO Year | 1993 | 1962 |
| Metric | SPG | BDX |
|---|---|---|
| Price | $183.23 | $193.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $188.64 | ★ $212.13 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.83% | 2.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.87 | 5.82 |
| Revenue | $6,155,275,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | $3.35 | $3.40 |
| P/E Ratio | ★ $26.54 | $33.26 |
| Revenue Growth | 4.17 | ★ 8.24 |
| 52 Week Low | $136.34 | $162.29 |
| 52 Week High | $190.14 | $251.99 |
| Indicator | SPG | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 57.42 |
| Support Level | $181.35 | $189.44 |
| Resistance Level | $187.20 | $194.77 |
| Average True Range (ATR) | 2.79 | 3.77 |
| MACD | -0.06 | 0.21 |
| Stochastic Oscillator | 34.50 | 65.00 |
Simon Property Group is the largest retail real estate investment trust in the United States. Its portfolio includes an interest in 254 properties: 114 traditional malls, 108 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and 12 other retail properties. Simon's portfolio averaged $736 in sales per square foot over the trailing 12 months. The company also owns a 22% interest in Klépierre, a European retail company with investments in shopping centers in 14 countries, and joint-venture interests in 33 premium outlets across 14 countries.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.